Regeneron says half its COVID-19 treatment doses are being sent to 4 low-vaccination states
![Regeneron infusion center in Florida](https://cdn.mos.cms.futurecdn.net/tSc3XtXbMQCS2FwAZGBVoE-1024-80.jpg)
Health officials agree that if you are newly infected with COVID-19 and have an above-average risk of getting seriously ill, you should quickly seek treatment with Regeneron Pharmaceuticals' monoclonal antibody therapy. The federal government is covering the costs, some states have set up free infusion centers, and the antibody cocktail has been shown to reduce hospitalization rates by 70 percent for high-risk COVID-19 patients treated within 10 days.
"They are safe, they are free, they keep people out of the hospital and help keep them alive," Dr. Marcella Nunez-Smith, a senior adviser to the White House's COVID-19 response team, said at an Aug. 12 White House briefing.
But the loudest promotion of Regeneron's experimental treatment is coming from the governors of Texas and Florida, "where vaccinations lag and hospitalizations are soaring with Delta-variant infections" even as the governors "downplay vaccination and other measures that health officials say can prevent illness in the first place," Kaiser Health News reports. Texas Gov. Greg Abbott (R), who received Regeneron's lab-produced antibody cocktail earlier this month, on Wednesday banned government entities from requiring FDA-approved vaccinations.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
![https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516-320-80.jpg)
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The FDA approved Regeneron's treatment on an emergency use basis late last year, but few people used it as the vaccines became available and helped crush infections and hospitalizations. Then the Delta variant took hold. Since mid-July, Regeneron deliveries have "soared from 25,000 doses to 125,000 doses per week, with about half shipped to four states: Florida, Texas, Mississippi, and Alabama," Kaiser Health News reports, citing Regeneron spokeswoman Alexandra Bowie.
This "expensive, cumbersome, and difficult-to-use therapy" is "not a substitute for vaccine, by any means," Dr. Christian Ramers, an infectious disease specialist at Family Health Centers of San Diego, tells Kaiser Health News. "It's like playing defense with no offense."
Regeneron's infusions cost about $1,250 a dose, not counting the hundreds of dollars to transport the drug and administer the hour-long infusion, Kaiser Health News notes. "The federal government is also covering the costs of COVID vaccination, at about $20 a dose."
Both of those interventions are much less expensive than hospitalizing COVID-19 patients. But it's "fiscally irresponsible" and "downright despicable for 'small government conservatives' to look to the federal government to dole out the most extravagant rescues for their states when they've so willingly squandered — and impeded — the far more prudent and effective measures" like vaccines and masks, Neil J. Young writes at The Week.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
What could bring the US Steel-Nippon Steel merger back to life?
Today's Big Question President Trump opposed the deal. But he could be flexible.
By Joel Mathis, The Week US Published
-
'Orange juice also is facing a grander existential problem'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
5 of the scariest spiders in existence
The Explainer These creepy crawlers can be deadly
By Devika Rao, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published